Impact of IL28B (rs8099917) gene polymorphism on treatment response to Sovaldi, Daklinza, and Ribavirin in Egyptian patients with HCV infection

Infection by the hepatitis C virus (HCV) is a big threat to human health all over world. Many host factors could affect treatment response in HCV infection. One of these IL28B gene polymorphism. This research study investigated association (rs8099917) polymorphism with patients chronic infection receiving combination Sovaldi, Daklinza, and Ribavirin Egypt. The included 100 patients, divided into three groups based on outcomes: responders, relapsers, non-responders. Biochemical hematological analyses were performed, genotypes determined using PCR. genotyping was done real-time results showed high prevalence genotype 4 few 1. G allele associated higher risk developing relapse non-response, while TT significantly success. Viral load levels lower responders compared relapsers suggests that may be valuable predictor treated specified therapy. Further needed confirm fully understand findings.